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Abstract              
The scope and use of in vitro fertilisation (IVF), a technology which inherently 
presents gender inequalities, and its platform applications differ across countries 
according to respective legislation and regulation (Inhorn, 2015). Using the context 
of human germline genome editing (hGGE) as a framework, this article will explore 
and discuss whether differences in legislation and regulation across countries force 
individuals/couples to seek transnational care to fulfil their reproductive desires. This 
article will primarily focus on regulation and practices in the United Kingdom (UK) 
and use these as a comparative to regulation and practices in other countries. The 
primary research upon which this article is based was conducted in the UK between 
1st March 2018 – 31st October 2019. The research consisted of a largely qualitative, 
online public survey with a final data set of 521 respondents, semi-structured 
interviews with 11 experts/professionals who were/are involved in the scope of hGGE 
in the UK, and semi-structured/interactive interviews with 21 people affected by a 
respective range of genetic conditions. The findings reveal that 65.64% of respondents 
were supportive of people utilising transnational care to achieve their reproductive 
desires in relation to hGGE and that 76.39% felt they should not be prosecuted if they 
do.  
Keywords: genome Editing, In Vitro Fertilisation, reproduction, transnational care  
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Forzar los Viajes de Cuidado Transnacional? 
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Resumen 
El alcance y el uso de la fertilización in vitro (FIV), una tecnología que presenta de forma 
inherente las desigualdades de género, y sus sistemas de aplicación difieren entre los países 
de acuerdo con la legislación y la regulación respectivas (Inhorn, 2015). Utilizando el 
contexto de la edición del genoma de la línea germinal humana (hGGE) como marco, este 
artículo explorará y discutirá si las diferencias en la legislación y la regulación entre países 
obligan a las personas / parejas a buscar atención transnacional para cumplir sus deseos 
reproductivos. Este artículo se centrará principalmente en la regulación y las prácticas en 
el Reino Unido (UK) y las utilizará como una comparación con la regulación y las 
prácticas en otros países. La investigación principal en la que se basa este artículo se 
realizó en el Reino Unido entre el 1 de marzo de 2018 y el 31 de octubre de 2019. La 
investigación consistió en una encuesta pública en línea en gran parte cualitativa con un 
conjunto de datos final de 521 encuestados, entrevistas semiestructuradas con 11 expertos. 
/ profesionales que estuvieron / están involucrados en el alcance de hGGE en el Reino 
Unido, y entrevistas semiestructuradas / interactivas con 21 personas afectadas por un 
rango respectivo de condiciones genéticas. Los hallazgos revelan que el 65.64% de los 
encuestados apoyaron a las personas que utilizan la atención transnacional para lograr sus 
deseos reproductivos en relación con hGGE y que el 76.39% sintió que no deberían ser 
procesados si lo hacen. 
Palabras clave: edición genómica, Fertilización In Vitro, reproducción, atención 
transnacional  
GÉNEROS –Multidisciplinary Journal of Gender Studies, 9(2) 186 
 
 
his article explores attitudes towards transnational care using 
technologies for the prevention of genetic disorders as a 
framework. This article draws upon primary research to question 
whether seeking to use such technologies could force people to seek 
transnational care.  
In vitro fertilisation (IVF) is a procedure in which eggs are fertilised by 
sperm outside of the body (Franklin, 1997). This procedure was originally 
developed to assist couples experiencing difficulties with fertility to have a 
genetically related child (Franklin, 1997) but is now used as a platform to 
enable several other reproductive choices (Wang & Sauer, 2006). Such 
choices include surrogacy (a woman gestating and giving birth to a baby for 
another person or couple), gamete freezing (freezing egg or sperm cells for 
later use), gamete donation (donated gametes being combined with a parent’s 
gametes to create embryos), and preimplantation genetic testing (testing 
embryos created via IVF for a genetic condition of which there is a family 
history, formally known as preimplantation genetic diagnosis (PGD)) 
(Zegers-Hochschild et al., 2017). More recently, a genetic editing technique 
known as CRISPR-Cas9 has been used in conjunction with IVF to enable the 
genomic material (DNA) in human embryos (germline cells, i.e. cells which 
are heritable) to be edited (Morrison & Saille, 2019). While this latter 
application is not widely established, it is highly controversial and has 
unearthed international discussions on whether its use should be developed 
and/or permitted among reproductive choices, and if so, to what extent.  
Following the birth of Louise Brown in 1978, the first baby born as a result 
of IVF (Wang & Sauer, 2006), the use of IVF has grown into a global multi-
billion pound industry (Grand View Research, 2019). Her birth signified a 
monumental breakthrough in science and technology and ignited hope for 
those with fertility difficulties (Franklin, 2013). Prof. Sarah Franklin, an 
anthropologist turned sociologist with pioneering research in reproductive 
technologies, thus writes that IVF is a hope technology (Franklin, 1997) and 
this is reinforced by its surroundings statistics. IVF has a modest success rate 
of around 24% which steeply declines as maternal age advances (HFEA, 
2018b). This means that roughly only 1 in 4 people who utilise IVF services 
achieve their desired outcome. However, despite this modest success rate, 
individuals/couples are not deterred from utilising the technology and its 
continued use has generated a shift in public attitudes towards assisted 
T 
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reproduction technologies (ARTs) (Bonetti et al., 2008; Fauser et al., 2019). 
Among the shift in attitudes is trust (Fauser et al., 2019); trust that the use of 
ARTs will not have catastrophic consequences (presumed by the resulting 
births of children with no explicit abnormalities) and that such technologies 
are therefore safe. The assumed safety however does not account for the 
unequal health and socioeconomic demands contemporary IVF practices 
place on women or the associated risks they encounter as a result (NHS, 
2017b; Inhorn, 2015; Franklin & Roberts, 2006).  
Women who undergo IVF are most commonly required to inject 
themselves with hormones for several weeks before her eggs are surgically 
removed (Franklin & Roberts, 2006; Stock, 2003). This is so that a 
menopause-like state can be induced and more than one egg can be stimulated 
to mature (Fauser & Devroey, 2003). This process presents the woman with 
several significant risks which men undergoing IVF are not subjected to. The 
hormone injections can present with unpleasant side-effects which can include 
changes in mood, headaches, hot flushes and restlessness/irritability (Fauser 
& Devroey, 2003). While those side-effects may seem minor, the woman is 
also at risk of ovarian hyperstimulation syndrome which is when too many 
eggs develop in her ovaries and they become enlarged and often very painful 
(Fauser & Devroey, 2003). Symptoms of this syndrome can include weight 
gain (from a build-up of fluid), nausea and vomiting, dehydration, and 
breathing difficulties (Vlahos & Gregoriou, 2006). Additionally, the 
syndrome can become so severe that blood clots can form inside the woman 
and these can have fatal consequences (Vlahos & Gregoriou, 2006). In 
comparison, men undergoing IVF are simply required to ejaculate into a 
container and are not subject to any invasive procedures or their associated 
risks. In this context, IVF is a technology which inherently presents with 
gender inequalities. Such inequalities are not limited to the process of IVF and 
can extend to the sociocultural use of them (Inhorn, 2015). 
The growth and availability of IVF has seemingly normalised its use 
regardless of the risks involved (Franklin & Roberts, 2006). According to 
Prof. Marcia Inhorn, a medical anthropologist, this normalisation can make 
women feel like they have a duty to subject themselves to the risks and costs 
of IVF if their quest for a genetically related child is not fulfilled through their 
sexual practices (Inhorn, 2015). Similarly, women often feel that they are held 
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responsible for the health and wellbeing of their children (Inhorn, 2015; 
Franklin & Roberts, 2006; Kerr, 2004). While some factors of a child’s health 
and wellbeing may be controllable and/or influenced by environmental factors 
such as nutrition and physical activity (Murphy et al., 2018), other factors, 
such as genetics, are less controllable (Kerr, 2004; Boardman, 2017). In the 
UK, 30,000 babies and children are diagnosed with a genetic condition each 
year (Genetic Disorders UK, 2020a). Some of these conditions have no family 
history and are therefore termed ‘de novo’, which means that are new to a 
person’s genetics (Veltman & Brunner, 2012), while others do. In cases of the 
latter, perspective parents (often the woman to a greater extent) can be faced 
with difficult choices on how they should form their family (Kerr, 2004).  
Advances in healthcare and genetic testing for heritable disorders have 
enabled an increasing number of diagnoses to be made and for people with 
genetic conditions to have a wider range of reproductive choices (Kaur & 
Border, 2020; Boardman, 2017) While adoption or not having children were 
once generally the only options for such people, perspective parents can now 
opt to use donated gametes to conceive a child or preimplantation genetic 
testing (PGT) (Boardman, 2014; Franklin & Roberts, 2006). PGT is currently 
the only option which can enable both parents to be genetically related to a 
child without a specific genetic condition being passed on to it (Kaur & 
Border, 2020), but is reliant on IVF and its associated gender based risks and 
inequalities. The availability of such choices have been found to impact what 
people affected by genetic conditions believe people think about them (Kerr, 
2004; Boardman, 2014; Shakespeare, 2017). Boardman (2017) found that 
lived experiences with a genetic condition influence reproductive decisions. 
This is significant because as advances in genetic testing continue, PGT could 
become an option for a greater number of conditions and individuals/couples 
may feel obligated to subject themselves to such services and the gendered 
inequalities inherent to them (Boardman, 2014, 2017; Boardman & Hale, 
2018).  
However, PGT is focused upon created embryos not being affected by a 
given condition in order for them to be considered viable for transfer into a 
uterus. This means that if all created embryos test positive for the parent’s 
condition, the couple will not have a viable embryo (Franklin & Roberts, 
2006). The couple can subject themselves to IVF for PGT again but this is 
dependent on several factors. Firstly, the couple has to be willing to go through 
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IVF again, including all the impacts on and risks to the woman (Fauser & 
Devroey, 2003; Franklin & Roberts, 2006). Second, the couple has to consider 
the emotional and financial expenses of PGT and whether they can afford 
them (Franklin & Roberts, 2006). Many researchers have found that the desire 
to have a genetically related child supersedes most rational decisions and that 
couples will go through great lengths to achieve their reproductive desires 
(Franklin & Roberts, 2006). These decisions include accruing debts into the 
thousands and travelling abroad to access clinics which are perceived to offer 
greater promise and/or services not available in their country of residence 
(Inhorn, 2015). The notion of travelling abroad to access ARTs is a form of 
transnational care which has been termed as ‘reproductive travel’ and 
shortened to ‘reprotravel’ by Prof. Inhorn (2015a).  
Reprotravel is a growing phenomenon which is exacerbated by the 
variations in legislation and regulation of ARTs in different countries (Inhorn, 
2015). In the UK, ARTs are regulated by the Human Fertilisation and 
Embryology Act 1990, as amended (Parliament UK, 1990). This Act is 
enforced by the Human Fertilisation and Embryology Authority (HFEA), an 
independent body established to licence, monitor and inspect all fertility 
treatment and research involving human embryos outside of the body (Genetic 
Alliance UK, 2019). Under the Act, PGT is only permitted for medical 
purposes. In contrast, in the United States (US), PGT can be used for sex-
selection and to select embryos based on non-medical characteristics such as 
eye-colour and hair-colour (Bennett, 2016; Shanks, 2018). While these non-
medical possibilities may not seem significant enough to compel a couple to 
subject themselves to the complexities of IVF for PGT, such choices may 
appeal to some couples. For example, in eastern countries where sex-selection 
for non-medical purposes is prohibited, couples have utilised reprotravel to 
achieve their reproductive desires based on sociocultural expectations 
(Inhorn, 2015; Rosemann et al., 2019). Such choices are usually motivated by 
cultural factors such as the historical one-child policy in China (Hesketh et al., 
2005), and/or to avoid the expense associated with dowries (Sudha & Rajan, 
1999). Considering that individuals/couples are motivated to reprotravel for 
such factors, the lengths perspective parents may be willing to go through to 
prevent a child being born with their condition could be even greater.  
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Many people seek transnational care to access bespoke clinical research trials 
and innovations (Bell et al., 2015; Rosemann et al., 2019). In such cases, trials 
often offer hope as a last resort and sometimes they may be the only source of 
hope (Bell et al., 2015). As indicated above with the IVF industry, people will 
seek hope and take their chances regardless of projected success rates and the 
associated gendered risks and inequalities (Franklin, 1997; HFEA, 2018a). A 
developing biotechnology which could be added to ARTs is human germline 
genome editing (hGGE) (Ormond et al., 2017). This is when the DNA in egg, 
sperm or embryo cells is either added to, removed or replaced (Morrison & 
Saille, 2019). Such edits could change the characteristics of the individual 
born as a result from them and could be passed on to future generations 
(Ormond et al., 2019). This means that any potential benefits and/or 
unforeseen side-effects could both also be passed on to future generations 
(Morrison & Saille, 2019). For this reason, there is ongoing international 
contentions on whether this technology should be developed and/or permitted 
for potential clinical use (Greenfield, 2019; Rosemann et al., 2019).  
The most compelling reason advocated for developing hGGE is for the 
prevention of serious monogenic (single-gene) disorders (Daley et al., 2019). 
In theory, successful clinical application of hGGE could end a family’s 
prevalence of a disorder for which they have a history (Ormond et al., 2019). 
This technology could also increase the number of viable embryos following 
PGT so women may not need to feel compelled to undergo IVF treatment 
several times to achieve their reproductive desires (Coller, 2019). Potentially, 
hGGE could therefore alleviate women from undergoing IVF more than once. 
This could save women from the associated gendered risks and socioeconomic 
burdens of IVF, should they wish to have a genetically related child to 
themselves and their child’s father free-from their history of a given genetic 
disorder. In this context, a demand for hGGE should it ever be considered safe 
enough for clinical application is foreseeable, as is utilising reprotravel to 
access it (Rosemann et al., 2019).  
  
Genetic Disorders and hGGE 
 
Scientists currently estimate that there are around 10,000 monogenic disorders 
of which 4,000-6,000 are diagnosable but rare (World Health Organization, 
2020; Rare Disease UK, 2020; Nuffield Council on Bioethics, 2018). 
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Information about such disorders continues to advance and geneticists are 
working towards understanding the genetic bases of these disorders in greater 
depth (Nuffield Council on Bioethics, 2018). Disorders are usually the result 
of a mutation in a person’s DNA (Lovell-Badge, 2019). DNA is represented 
by four letters, A, C, G, and T, the sequence of which determines the 
characteristics and functions a person has and/or exhibits (Komor et al., 2016). 
By knowing the general sequences of DNA for respective characteristics and 
functions, deviations from these can be identified as mutations and disorders 
can be diagnosed (Komor et al., 2016; Ormond et al., 2017). A recent project 
in the UK named the 100,000 Genomes Project, looked at the entire DNA 
sequences (the genomes) of 85,000 people, 15,000 of which were explored 
twice to generate a database of 100,000 genome sequences (Genomics 
England, 2014). Analyses of the sequences in the database (among other 
objectives) are hoped to reveal the genetic foundations for more of the 10,000 
monogenic disorders thought to exist so that these can be tested for and 
diagnosed (Genomics England, 2013).  
In the UK, to access genetic testing an individual/couple must request a 
referral from their general practitioner (GP) or have tested positive for a 
condition during routine pregnancy screening (NHS, 2019). A referral can 
take several weeks before a date for an initial consultation with a genetic 
consultant is booked (Genetic Disorders UK, 2020b). At a consultation, the 
individual’s/couple’s family history will be taken, a physical examination will 
be conducted and blood or saliva samples will be taken for analysis if a test is 
requested (NHS, 2019). A referral to a genetic counsellor will also be made if 
genetic tests are requested by the consultant (NHS, 2019). If a consultant does 
not share the individual’s/couple’s concerns of having a possible genetic link 
to a condition, they can refuse to request tests or to test for specific genes 
(Genetic Disorders UK, 2020b). If specific genes can only be tested for in 
specific countries, this can be another reason for transnational care being 
sought and/or utilised. However, in England, in continuation from the 100,000 
Genomes Project, a genomic medicine service was launched in 2018 which 
offers whole genome sequencing (NHS England, 2019). This could also serve 
as a route through which testing can be sought (NHS, 2019). These services 
are currently available to UK citizens via the UK’s national health service 
(NHS) if requested by a consultant, however, due to the UK’s political 
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economy this may not be sustainable. Should an individual/couple 
choose/need to access genetic testing services privately, these can cost 
between £500-£2000 or more (NHS, 2017a). There are also direct-to-
consumer genetic testing services such as 23andMe but results from these may 
not be considered reliable (Genetic Disorders UK, 2020b). In any case, 
obtaining results from genetic tests can take several months but are important 
for diagnostic reasons (Genetic Disorders UK, 2020b).  
A diagnosis can be imperative for an individual’s/a couple’s reproductive 
choices (Nelkin & Lindee, 2004). A diagnosis can be given with a risk 
percentage of an individual’s/couple’s offspring being affected by a given 
condition and this can influence family planning decisions (NHS, 2019). For 
example, if there is 25% chance a child may be affected by a condition, the 
individual/couple may opt to conceive without ARTs, while if there is 75% 
chance, ARTs may be chosen instead. However, while a diagnosis can be 
made without knowing the exact gene for a condition, a risk percentage cannot 
be determined without it (Genetic Disorders UK, 2020b). In this context, 
knowing the gene for a condition can be vital for considering options, choices 
and possible interventions which is why data from the 100,000 genomes 
project could prove to be invaluable (Genomics England, 2014). The same 
data could also be used to develop treatments and preventative interventions 
such as hGGE once gene associations have been identified. A gene for a 
condition would have to be identified for hGGE to be developed as an 
intervention for it and for it to be a possible intervention to prevent a given 
condition (Ormond et al., 2017).  
hGGE has gained widespread attention in the past eight years due to the 
discovery of a genome editing technique called CRISPR-Cas9 (Ormond et al., 
2017). CRISPR is the abbreviation for clustered regularly interspaced 
palindromic repeats (Morrison & Saille, 2019). This is reference to how the 
technology essentially works, i.e. bacteria are programmed to locate a specific 
sequence of DNA and bind itself to it (Ormond et al., 2017). The ‘Cas9’ 
component, which is an enzyme, then breaks the stands of DNA so that repair 
mechanisms are activated (Anzalone et al., 2019). As the repairs are made, the 
targeted sequence of DNA can be modified (Anzalone et al., 2019). This 
technique is far more efficient, methodologically and financially, than other 
genome editing techniques (Morrison & Saille, 2019). This efficiency has 
widened the potential applications for genome editing and has enabled 
193 Amarpreet Kaur – Could Seeking Human Germline Genome 
Editing Force Journeys of Transnational Care? 
 
 
scientists across the globe to develop its uses, one of which is for hGGE 
(Ormond et al., 2017). However, while the technology could be used to 
prevent genetic disorders, if people have access to and are willing to use it, 
hGGE could also be used to generate genetic disorders, both unintentionally 
and intentionally (Ormond et al., 2019). The fear surrounding the latter 
possibilities continue to influence policies, legislation and regulation of hGGE 
across the globe.  
 
Legislation and Regulation  
 
Most scientists err on the side of caution when genome editing techniques are 
considered for applications involving hGGE. This is because the invasive 
technology could have unforeseeable side-effects that could transcend into 
future generations (Coller, 2019; Ormond et al., 2019). However, in 
November 2018, on the eve of an international summit on human genome 
editing, news broke that twin girls had been born in China following the use 
of hGGE (Lovell-Badge, 2019). The unexpected news was received with 
palpable shock and horror, and scientists at the summit were quick to 
scrutinise and publicly condemn the work of the lead scientist responsible for 
the twins’ birth (Daley et al., 2019). Scientists continue to claim that the 
methods used to make the edits meant that they could not have been successful 
and that the technology is yet to be considered safe for any clinical trial (Daley 
et al., 2019). Additionally, the couples involved in the research are thought to 
have been misled and consequently the women would have been 
unnecessarily subjected to the gendered risks of IVF. As such, following the 
news, several international initiatives were launched in response to it and the 
Chinese scientist who instigated the birth of the twin girls has been sentenced 
to serve three years in prison (Sample, 2019). However, these advances have 
not deterred a Russian scientist from wanting to conduct similar research 
(Cyranoski, 2019), and many countries still do not have clear legislation 
and/or regulation for hGGE (Yotova, 2017).  
Due to the variations in legislation and regulation across countries, such 
research is currently possible in many countries through public and/or private 
funding. Scientists in the US and other countries where research involving 
hGGE is not carefully regulated and/or have strong underlying histories 
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involving eugenics, such as China and Germany, have called for a global 
moratorium on hGGE (Lander et al., 2019). The political and economic 
structures in such countries perhaps explain their motivations and support for 
this call. In comparison, the UK, who would have no need to participate in a 
moratorium due to its own fairly robust legislation and the HFEA have no 
intention of participating in any such moratorium (Kaur & Border, 2020). 
These differences mean that the development of hGGE if added to ARTs 
could motivate perspective parents with genetic conditions to utilise 
reprotravel to access hGGE to achieve their reproductive desires (Rosemann 
et al., 2019). In this context, international initiatives launched in 2019 could 
serve to generate a shared grounding for all involved in the development of 
hGGE regardless of the country in which they work and/or reside. Such 
initiatives could potentially alleviate some of the socioeconomic and cultural 
inequalities that could surround accessing the technology and the 
implications, as detailed above, these have for women. 
The first initiative was convened by the UK’s Royal Society, the US 
National Academy of Science and the US National Academy of Medicine in 
March 2019, and is the International Commission on the Clinical Use of 
Human Germline Genome Editing (The Royal Society, 2019). The 
commission have held several public meetings and webinars to address issues 
surrounding hGGE, in Washington and London, which will inform its work 
and conclusions (The National Academies of Science, Engineering, and 
Medicine, 2019; The Royal Society, 2019). It is aiming to develop principles, 
criteria and standards for the clinical use of genome editing of the human 
germline and is anticipated to publish these in 2020. While countries may 
choose not to adopt the commission’s conclusions, many anticipate that they 
will be widely welcomed and adhered to. The second initiative is led by the 
World Health Organization’s Expert Advisory Committee on Developing 
Global Standards for Governance and Oversight of Human Genome Editing. 
The committee has developed a global registry which aims to track all clinical 
trials and research involving human germline cells, and launched this in 
August 2019 (World Health Organization, 2019b). The committee also aims 
to advise and make recommendations on mechanisms for governance of 
hGGE in 2020 (World Health Organization, 2019a). The committee’s 
recommendations may be more relevant to some countries than others, but are 
195 Amarpreet Kaur – Could Seeking Human Germline Genome 
Editing Force Journeys of Transnational Care? 
 
 
hoped to even transnational inequalities regarding access to and the use of 
hGGE.  
There are several countries which, under the Convention for the Protection 
of Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine, commonly referred to as the Oviedo 
Convention, have agreed not to utilise hGGE, but these are few in a global 
context (Council of Europe, 2011). Article 13 of the convention states that 
‘An intervention seeking to modify the human genome may only be 
undertaken for preventive, diagnostic or therapeutic purposes and only if its 
aim is not to introduce any modification in the genome of any descendants’ 
(Council of Europe, 1997). Article 13 therefore prohibits hGGE as 
modifications could be introduced to future descendants as a result of utilising 
the technology. UK legislation currently intends to prohibit all clinical 
applications of hGGE but this needs to be readdressed if the UK is aiming to 
robustly uphold this stance (Kaur & Border, 2020). This is because the 
prohibitions in the HFE Act specifically relate to women who have been 
female from birth (i.e. ciswomen) (Parliament UK, 1990). As such, because 
of ongoing scientific advances with womb transplants, transwomen and/or 
men could choose to gestate and birth children which have had their germline 
cells edited. Such possibilities would not be prohibited from being licenced 
by the HFEA under the Act so long as the embryo is transferred within 14 
days from its creation (Kaur & Border, 2020). Nonetheless, legislation in the 
UK is otherwise relatively clear and the HFEA are renowned for its regulation 
of ARTs. In the above context, the committee’s recommendations may not 
hold much relevance to these countries.  
In contrast, countries such as the US and China may substantially benefit 
from the recommendations that the committee makes. These countries are 
highlighted as the unregulated practices in these countries are of global 
concern to humanity (Baylis, 2019). In the US biohackers conduct unregulated 
experiments using genome editing technologies in the belief that they are 
advocating for fairer access to the technology (Baylis, 2019). While 
biohackers may facilitate fairer access, they cannot ascertain whether their 
followers and audiences have considered the repercussions and consequences 
of experimenting with genome editing technologies to the extent they have. 
In such cases later regret is too late to undo the catalyst to events that could 
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unfold. In China, as mentioned above, scientists have already unsuccessfully 
trialled hGGE (Lovell-Badge, 2019; Daley et al., 2019) and consequently 
women have been unnecessarily subjected to the associated gendered risks. 
This was possible due to the nuances of legislation and regulation in China 
(Sample, 2019). While the consequences of experiments and research in these 
countries cannot be undone, further premature applications of hGGE could be 
prevented and women could be spared from the gendered risks associated with 
IVF, if such countries adopt the recommendations that WHO’s expert 
advisory committee publish.  
 
Methodologies 
 
In order to ascertain UK public’s views on reprotravel, part of a mixed-
methods, online public survey conducted between 1st March 2018-31st May 
2018, questioned respondents’ views on reprotravel and prosecution. The 
survey was titled ‘Understandings of Genetic Editing and its Potential Uses 
with Human Reproduction’. The survey was designed using Qualtrics 
software and was aimed at people living in the UK aged 16 or over, who were 
willing to participate voluntarily. To avoid any potential bias, respondents 
were given no incentive or compensation for their time taken to complete the 
survey. The respondent sample was weighted on four demographic factors; 
gender, age, religion and whether the respondent is affected by a genetic 
condition. The latter two demographics were deemed significant as they are 
often anticipated to have strong views on genome editing (MacGillivray & 
Livesey, 2018).  
The final sample consisted of 521 respondents, 52% of which self-
identified as female, aged 16-82, (rounding the numbers) 37% of which self-
identified as religious and 29% as being affected by a genetic condition. 
Respondents were also asked to state their occupation, which to an extent 
could indicate their socioeconomic status and/or level of education. 
Respondents included professionals, skilled workers, some who were 
unemployed at the time of completing the survey and some who were retired. 
These demographics are detailed alongside respondents’ answers shared in the 
findings section in this article. The majority of respondents had no direct 
expertise or professional interest in hGGE technologies and are therefore 
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considered to be the wider public in the UK. The findings from the survey 
were reached using mixed-method analysis via SPSS and NVivo software.  
The survey consisted of four sections; the first was on knowledge and 
understanding of genome editing, the second on hypothetical practical 
applications relating to factors of disease, the third was on regulation and 
ethics, and the final section captured the demographic information shared 
above. Findings from the survey were used to inform 11 semi-structured 
interviews with professionals/experts who could speak to the future of hGGE 
in the UK and/or who could provide the most up to date information on hGGE. 
The semi-structured interviews sought to ascertain the existing scientific and 
legal parameters of hGGE in the UK and to explore how they could expand to 
enable hGGE for clinical applications. Data from some of these interviews 
informed the questions and activities for 11 interactive interviews with a total 
of 21 people affected by a respective range of genetic conditions. Some of 
these interviews were conducted in groups of 4-5 people, in pairs or one-to-
one depending on the participants health and availability either via Adobe 
Connect software or in accessible public meeting rooms.  
All the interviews were transcribed and then imported to NVivo software 
for analysis. Analysis consisted of core themes being identified and then 
transformed into overarching categories for further exploration and/or 
consideration, such analysis would traditionally be considered a mix between 
grounded theory and thematic analysis (David & Sutton, 2004; Mason, 2017). 
Findings from these interviews will also be discussed in this article. All the 
primary research detailed in this section received ethical approval from the 
University of Cambridge’s Department of Sociology’s Ethics Committee 
prior to being conducted, and conformed to the British Sociological 
Associations guidelines on conducting ethical research (British Sociological 
Association, 2017). As such, all participants and respondents provided 
informed consent for the research they chose to be part of and where 
appropriate/possible participants were given the right to right to withdraw to 
a specified date.  
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Findings and Discussion  
 
4.8% (25/521) of respondents to the survey felt that hGGE should not be 
legalised in the UK for clinical application. The remaining respondents were 
either supportive of hGGE being legalised in the UK for clinical application, 
such as preventing children being born with a given genetic disorder, without 
reservation or supportive depending on various factors. These findings 
support findings from a survey commissioned by the Royal Society (van Mil 
et al., 2017) and suggest that a significantly large majority of the UK 
population are supportive of hGGE for clinical applications. A large 
proportion of the support for clinical application of hGGE did however come 
with several reservations. Respondents felt that robust regulation to prevent 
misuse of hGGE, i.e. any use that is not for medical benefit, is primal to it 
being permitted beyond research purposes. This is evidenced by the following 
answers from respondents:  
 
It [hGGE] has the potential to make a huge difference to the quality of 
life of so many people. However, it would need legislating really really 
carefully in order that it not be misused.  
(Respondent 63: Female, 31, Midwife, not religious, not affected)  
[There] Needs to be very careful control of the process. Once it [hGGE] 
is tried and tested for preventing disease and illness where is the line 
drawn? Could make arguments for all sorts of ‘improvements’ and 
move towards some dystopian future.  
(Respondent 56: Male, 22, Undergraduate Student, not religious, not 
affected) 
 
Professionals/experts in the field assert that any future amendments to the 
HFE Act would only permit hGGE for medical purposes, and that should it be 
permitted, this would initially only be for ‘serious monogenic disorders’ and 
where there is ‘an unmet medical need’. This intention however only pertains 
to the UK. The WHO’s expert advisory committee’s forthcoming 
recommendations (World Health Organization, 2019a) may assist on 
addressing this reservation on a wider scale if they support this assertion and 
if the recommendations are adopted by other countries.  
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Respondents also held reservation towards the potential clinical application of 
hGGE on there being proven, transparent, safety and success of the 
technology, this included highlighting the risk of any negative side effects 
hGGE could have. The following answers from respondents evidence this 
claim:  
 
If it is safe, affordable and the level of success is high. 
(Respondent 50: Male, 41, PhD Student, not religious, not affected)  
If genetic editing works efficiently and safely, it should be available to 
all people who can benefit. If there are risks, these should be well 
understood and explained so that an informed choice can be made. 
(Respondent 323: Male, 56, Computer Programmer, religious but no 
influence, not affected)  
 
Scientists in the UK are very mindful of this reservation and continuously 
proceed with extreme caution when addressing the efficacy of current hGGE 
techniques. Discussions with Professor Robin Lovell-Badge and Dr Kathy 
Niakan, Biologists at the Francis Crick Institute in London, reassure such 
caution. While both of these prominent scientists are supportive of permitting 
hGGE for potential clinical application, neither hesitate to emphasise that 
current hGGE are still developing and are not yet efficient enough for clinical 
application. Their cautious manners speak to ethical, moral and scientific 
principles which were lacking in the research conducted in China, and which 
Biohackers in the US seemingly do not prioritise (Baylis, 2019). While the 
UK population may be assured that scientists in the UK are capable of 
governing themselves in accordance to widespread ethical, moral and 
scientific principles, this is evidently not true of scientists in some other 
countries (Lovell-Badge, 2019). The suggested moratorium outlined earlier in 
this article may have been one way of acknowledging this matter, but the 
International Commission’s work towards developing standards for clinical 
uses of hGGE is perhaps a more pragmatic approach. The commission’s 
forthcoming standards, if they are adopted, could ensure that hGGE is not 
prematurely used in clinical applications in countries where ethical and moral 
principles are not at the core of scientific practices. These could also serve to 
protect women from unnecessary gendered risks associated with IVF, 
pregnancy, and childbirth, and the impacts these can have on their long-term 
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health and the gendered unequal expectations of rearing and caring for any 
resulting children (Coller, 2019).  
Inspired by Inhorn's (2015) research, a subsequent question in the survey 
queried views on whether people living in the UK should be allowed to travel 
abroad to access hGGE if it was not legalised in the UK for clinical 
applications. 65.64% (342/521) of respondents were in favour of this 
proposition and only 7.49% (39/521) of respondents were explicitly against 
it. This suggests that the majority of respondents hold fairly liberal views 
towards reprotravel in relation to it being utilised to circumvent UK 
legislation. The remaining 26.87% (140/521) of respondents held reservations 
based on several factors. Such factors included the intent for seeking genome 
editing, the reason why hGGE was not legal in the UK, the safety of hGGE 
outside of the UK, how follow-up care would be navigated through 
transnational borders, and the difficulty of preventing people from utilising 
reprotravel. These factors are evidenced by the following answers from 
respondents.  
 
Should be depending on the reason for wanting genetic editing. Travel 
and being able to travel abroad is usually only available to those who 
are wealthy. Becomes a rich man's game.  
(Respondent 144: Female, 34, Manager, religious but no influence, not 
affected)  
It will depend on the reasons for why it is illegal. Would legislators have 
a reason to think that this would interfere with domestic welfare, health, 
or security?  
(Respondent 320: Male, 28, Researcher, not religious, not affected)  
Safety. We have an NHS which puts the welfare of the patient first. 
Some other countries operate healthcare on who can afford it, which 
creates a culture of huge disparity in access to quality healthcare 
options. If it is available, it should be available to all who need it not 
just those with money.  
(Respondent 173: Female, 44, Professional, not religious, has 
condition)  
Availability of trained professionals to be able to deal with any follow 
up care/intervention back in the UK. Cost would also be a bit of an issue 
if the person could not self-fund the treatment.  
(Respondent 327: Male, 34, Cancer Research Nurse, not religious, not 
affected)  
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Impossible to police. 
(Respondent 281: Male, 32, Driving Instructor, not religious, has 
condition)  
 
These factors are translatable to citizens in other countries as the same 
considerations are accountable. The specific sociocultural, political and 
economic contexts which influence individuals’/couples’ motivations to 
utilise reprotravel may differ according to the countries in which they reside 
but these are likely to be pertinent to the sociocultural context of a given 
country (Inhorn, 2015). For example, hGGE is not being used in clinical 
applications in the UK because it is not yet considered to be safe enough, but 
if UK citizens travelled abroad to access the technology, upon return, medical 
professionals in the UK may not have the expertise to deal with complications 
arising from it (Bell et al., 2015; Rosemann et al., 2019). In this scenario, the 
lack of availability in the UK, in addition to other factors, is designed to 
protect its citizens from adverse side-effects for which its healthcare system 
and professionals are not yet prepared, circumventing this through reprotravel 
therefore threatens this ability. As such, individuals/couples may benefit from 
taking the underlying context of practices in their country of residence into 
consideration before accessing transnational care. This could prove to be 
particularly sagacious in relation to the growing industry of reprotravel and 
the upcoming risky possibilities that could be made available through it 
(Grand View Research, 2019; Ormond et al., 2019). Women can prevent 
themselves from being subjected to the gendered risks of IVF and the risks of 
its platform applications by challenging the necessity if accessing them and 
critically assessing the safety of them, in their country of residence and/or 
abroad.  
Perhaps surprisingly, 76.39% (398/521) of respondents felt that even if 
hGGE were to remain illegal in the UK for clinical applications, people who 
live in the UK should not be prosecuted if they were to travel abroad to access 
it. This is because respondents largely felt that only people who are really 
desperate to have a genetically related child without their disease are likely to 
utilise reprotravel to fulfil that desire. Respondents therefore also felt that 
hGGE would not be sought abroad for reasons that do not align with ethical 
and moral principals in the UK, i.e. for non-medical purposes such as eye-
colour or other aesthetic characteristics (Coller, 2019). However, a converse 
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reason for not wanting people to be prosecuted was because it would be 
difficult to police. This was also relayed by professional/experts in the field 
who highlighted that UK legislation is yet address reprotravel for purposes not 
supported in the UK and that people who do utilise reprotravel are hard to 
track. Respondents who felt that people should be prosecuted cited fines, 
imprisonment, refused re-entry to the UK and a ban from accessing care via 
the NHS as possible sanctions, but also recognised that enforcing these would 
be a challenge for the UK judicial system. In this context, while current 
legislation, regulation and/or practices in the UK could force its citizens to 
access hGGE abroad, acts to prevent children being born with genetic 
disorders would still be supported by the wider public in the UK. However, 
support towards such acts is also reserved due to their potential to exacerbate 
socioeconomic and gendered inequalities associated with ARTs and 
reprotravel.  
 
Conclusion  
 
This article detailed how IVF is considered to be a technology of hope and 
how such hope is reflected in its uptake despite its modest success rates 
(Franklin, 1997; HFEA, 2018a). This article then outlined the gendered risks 
that are inherent to current IVF practices (NHS, 2017b). It also claimed that 
the normalisation of IVF has led to a sociocultural discourse of women feeling 
a duty to utilise the technology to have a genetically related child if this desire 
is not fulfilled through their sexual practices (Inhorn, 2015). This article then 
argued that developments in genetic testing and diagnoses being made have 
increased reproductive choices for people living with genetic conditions 
(Genomics England, 2014; Wang & Sauer, 2006; Boardman, 2017). Such 
choices could expand to include hGGE, which in addition to preventing 
children being born with their parent’s condition, could mean that women do 
not need to undergo IVF multiple times to achieve their reproductive desires, 
thereby reducing the gendered risks and inequalities they are subjected to.  
However, the legislation and regulation of hGGE differs across countries 
(Yotova, 2017) and because of this some individuals/couples may feel forced 
to access transnational care. The forthcoming recommendations from two 
international initiatives launched in 2019, one regarding the governance and 
oversight of hGGE (World Health Organization, 2019a) and the other 
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regarding clinical standards (The Royal Society, 2019), are therefore duly 
anticipated and are hoped to even practices across countries. Findings from a 
survey which questioned UK publics’ views on reprotravel and interviews 
with professionals/experts in the field of hGGE revealed that a majority would 
support the clinical application of hGGE for medical purposes. They also 
revealed that the UK public largely feel that people should be able to travel 
abroad to access hGGE should it not be legalised for clinical application in 
the UK, and those that choose to do this, should not be prosecuted if they do. 
This support is nonetheless reserved on hGGE being robustly regulated and 
safe (Kaur & Border, 2020), and with caution that limited access to the 
technology could exacerbate socioeconomic and gendered inequalities within 
society.  
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